1) Oh, Y.; Kim, S.; Kim, Y.; Kim, H.; Jang, D.; Shin, S.; Lee, S. J.; Kim, J.; Lee, S. E.; Oh, J.; Yang, Y.; Kim, D.; Jung, H. R.; Kim, S.; Kim, J.; Min, K.; Cho, B.; Seo, H.; Han, D.; Park, H.; Cho, S. Y., Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy. Mol Cancer 2024, 23 (1), 155.
2) Min, K.; Zheng, C.-M.; Kim, S.; Kim, H.; Lee, M.; Piao, X.-M.; Byun, Y. J.; Kim, Y.; Joo, Y.; Cho, B.; Moon, S.; Kim, W. T.; Kang, H. W.; Park, H.; Yun, S. J., Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment. International Journal of Molecular Sciences 2024, 25 (20).
3) Min, K.; Kim, B. S.; Ha, Y. S.; Chung, J. W.; Jang, G.; Noh, M. G.; Ahn, H.; Lee, J. N.; Kim, H. T.; Yoo, E. S.; Kwon, T. G.; Chun, S. Y.; Park, H., Predicting septic shock in obstructive pyelonephritis associated with ureteral stones: A retrospective study. Medicine (Baltimore) 2024, 103 (31), e38950.
4) Kim, Y.; Kim, G.; Kim, S.; Cho, B.; Kim, S. Y.; Do, E. J.; Bae, D. J.; Kim, S.; Kweon, M. N.; Song, J. S.; Park, S. H.; Hwang, S. W.; Kim, M. N.; Kim, Y.; Min, K.; Kim, S. H.; Adams, M. D.; Lee, C.; Park, H.; Park, S. R., Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe 2024, 32 (8), 1380-1393 e9.
5) Kim, H.; Lee, E.; Park, M.; Min, K.; Diep, Y. N.; Kim, J.; Ahn, H.; Lee, E.; Kim, S.; Kim, Y.; Kang, Y. J.; Jung, J. H.; Byun, M. S.; Joo, Y.; Jeong, C.; Lee, D. Y.; Cho, H.; Park, H.; Kim, T., Microbiome-derived indole-3-lactic acid reduces amyloidopathy through aryl-hydrocarbon receptor activation. Brain Behav Immun 2024, 122, 568-582.
6) Min, K.; Kim, H. T.; Lee, E. H.; Park, H.; Ha, Y. S., Bacteria for Treatment: Microbiome in Bladder Cancer. Biomedicines 2022, 10 (8).
7) Lee, E.; Min, K.; Ahn, H.; Jeon, B. N.; Park, S.; Yun, C.; Jeon, H.; Yeon, J. S.; Kim, H.; Park, H., Potential Therapeutic Skin Microbiomes Suppressing Staphylococcus aureus-Derived Immune Responses and Upregulating Skin Barrier Function-Related Genes via the AhR Signaling Pathway. Int J Mol Sci 2022, 23 (17).
8) Ahn, H.; Min, K.; Lee, E.; Kim, H.; Kim, S.; Kim, Y.; Kim, G.; Cho, B.; Jeong, C.; Kim, Y.; Park, H., Whole-Transcriptome Sequencing Reveals Characteristics of Cancer Microbiome in Korean Patients with GI Tract Cancer: Fusobacterium nucleatum as a Therapeutic Target. Microorganisms 2022, 10 (10).
9) Yi, S. Y.; Park, D. J.; Min, K.; Chung, J. W.; Ha, Y. S.; Kim, B. S.; Kim, H. T.; Kim, T. H.; Yoo, E. S., Significance of albumin to globulin ratio as a predictor of febrile urinary tract infection after ureteroscopic lithotripsy. Yeungnam Univ J Med 2021, 38 (3), 225-230.
10) Min, K.; Yun, S. J.; Park, H.; Ha, Y.-S., Microbiome of Genitourinary Tumors: Especially in Prostate Cancer and Kidney Cancer. The Korean Journal of Urological Oncology 2021, 19 (3), 136-147.
11) Ha, Y. S.; Kim, S. Y.; Chung, J. I.; Choi, H.; Kim, J. H.; Yu, H. S.; Cho, I. C.; Kim, H. J.; Chung, H. C.; Koh, J. S.; Lee, J. Y.; Park, D. J.; Kim, H. T.; Yoo, E. S.; Kwon, T. G.; Min, K.; Kim, W. J.; Yun, S. J.; Park, J. H., Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study. World J Mens Health 2021, 39 (1), 158-167.
12) Min, K.; Chung, J. W.; Ha, Y. S.; Lee, J. N.; Kim, B. S.; Kim, H. T.; Kim, T. H.; Yoo, E. S.; Kwon, T. G.; Chung, S. K.; Tanaka, M.; Egawa, S.; Kimura, T.; Choi, S. H., Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy. World J Mens Health 2020, 38 (2), 226-235.